Allogene Share Price

Allogene Share Price

NASDAQ: ALLO | Micro Cap | Healthcare
$0.62
-$0.04 (-5.99%) Last updated on 21 Nov, 2026 | 02:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • About
  • Price history
  • FAQs

Allogene Stock Performance

Open
$0.65
Prev. Close
$0.66
Circuit Range
N/A
Day Range
$0.62 - $0.67
Year Range
$0.62 - $4.45
Volume
1,16,627
Average Traded
$0.64

Allogene Share Price Today

As of 22 November 2026, Allogene Therapeutics, Inc.'s share price is $0.62. The stock opened at $0.65, compared to its previous close of $0.66. During today's trading session, Allogene Therapeutics, Inc.'s share price traded between $0.62 and $0.67, with an average price of $0.65. Over the past 52 weeks, the stock has recorded a high of $4.45 and a low of $0.62. In terms of performance, Allogene Therapeutics, Inc.'s share price has declined by 71.43% over the last six months and is down 56.94% on a year-on-year basis.

Allogene Share Price Chart

Line chart of the Allogene price trend over the selected period. The price fell overall, ranging from 0.62 to 0.67, ending at 0.62.
$0.62$0.67
L
Show Current Price
H

Allogene Stock Fundamentals & Key Indicators

Market Cap
$137.73M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-0.50
Revenue (TTM)
$0.00
Return On Equity (TTM)
-44.44%
Profit Margin
N/A
Debt to Equity
0.00
Quarterly Earnings Growth YoY
-29.79%

Allogene Quarterly Profit & Loss

All figures in USD

ParticularsDec 2025Mar 2026Jun 2026Sep 2026
Revenue$0.00$0.00$4.64$0.00
Net Profit-$38.81-$42.61-$42.68-$50.37
Net Profit MarginN/AN/A-919.83%N/A
Income ChangeN/A-9.79%-0.16%-18.02%

Allogene Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$0.16$0.10$0.02$0.00
Net Profit-$340.41-$327.27-$257.59-$190.89
Net Profit Margin-212756.25%-327270.00%-1287950.00%N/A
Income ChangeN/A3.86%21.29%25.89%

Allogene Balance Sheet

All figures in USD Million

Particulars2025202420232022
Non Current Assets158.16245.32183.72292.76
Current Assets257.75303.39459.12528.82
Total Assets415.91548.71642.84821.58
Non Current Liabilities90.8591.0193.53100.97
Current Liabilities32.5135.5237.0853.73
Total Liabilities123.36126.53130.6154.7
Shareholders' Equity292.54422.18512.23666.88

Allogene Cash Flow

Annually

All figures in USD Million

Particulars2025202420232022
Operating-149.25-200.3-237.73-220.52
Investing95.5675.69163.29106.16
Financing30.16116.6895.72.95

About Allogene

Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).

Allogene Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Nov 2026
$1.20
$0.63
-46.47%
Oct 2026
$1.59
$1.18
-25.87%
Sep 2026
$1.99
$1.58
-24.34%
Aug 2026
$1.87
$2.10
+12.03%
Jul 2026
$2.05
$1.87
-9.88%
Jun 2026
$2.18
$2.08
-5.03%
May 2026
$2.09
$2.19
+2.82%
Apr 2026
$2.50
$2.13
-12.91%
Mar 2026
$2.67
$2.44
-12.54%
Feb 2026
$1.80
$2.79
+51.63%
Jan 2026
$1.35
$1.84
+34.80%
Dec 2025
$1.45
$1.36
-5.86%

Allogene Share Price FAQs